RxDoctor Payments Data

Jennifer Gradel

Family · Warrenton, MONPI 1700202959

Payments from drug & device makers

$3,365in general payments, 2019–2025

Across 176 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$952
  • AbbVie$386
  • Boehringer Ingelheim$330
  • Amgen$208
  • Corcept Therapeutics$200
  • Lilly USA, LLC$171
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,365 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$31,772
Medicare patients
95
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$60,441
JardianceEmpagliflozin36$55,107
OzempicSemaglutide38$52,810
TrulicityDulaglutide15$23,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,348
Repatha SureclickEvolocumab18$15,317
Incruse ElliptaUmeclidinium Bromide11$5,136
ArexvyRsvpref3 Antigen/As01e/Pf16$4,373
Insulin Lispro Kwikpen U-100Insulin Lispro11$2,692
Omeprazole91$1,844
Atorvastatin Calcium163$1,606
Gabapentin50$1,433
Novolog FlexpenInsulin Aspart14$1,431
Rosuvastatin Calcium108$1,156
Fesoterodine Fumarate ErFesoterodine Fumarate12$1,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$60,44172 claims
Boehringer IngelheimJardiance$330$55,10736 claims
Novo NordiskOzempic$75$52,81038 claims
GSKTrelegy Ellipta, Incruse Ellipta, Arexvy$86$28,85751 claims
Lilly USA, LLCTrulicity$171$23,82015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.

Other family in Warrenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →